Quality & complianceOfficial

FDA says clinical investigator's CAPA response falls short after CBER warning letter

🇺🇸 FDA CBER · Fri 20 Nov 2026

CBER told Florida-based Stephen J. Fallon, Ph.D., that his reply to an August warning letter did not fully resolve the violations and that he must submit a comprehensive CAPA plan.

The US Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) has told clinical investigator Stephen J. Fallon, Ph.D., of Wilton Manors, Florida, that his response to a warning letter did not completely resolve the issues raised. The letter is listed under ID 728673 and dated 13 November 2026. It was published on 20 November.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official source: FDA CBER ↗

Article written by VigiEye from the official source (FDA CBER). AI-assisted; check the source before acting.